Skip to main content
Erschienen in: Digestive Diseases and Sciences 6/2010

01.06.2010 | Original Article

Fecal Occult Blood Test in Patients on Low-Dose Aspirin, Warfarin, Clopidogrel, or Non-steroidal Anti-inflammatory Drugs

verfasst von: Mandeep S. Sawhney, Heather McDougall, Douglas B. Nelson, John H. Bond

Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Aim

To determine the effect of anticoagulants and antiplatelet medications on the positive-predictive-value of fecal occult blood test (FOBT).

Methods

All patients who underwent a colonoscopy at our institution from 1995 to 2006 for a positive FOBT were identified. Medical records were searched, and patients were stratified into five groups selected a priori: low-dose aspirin, NSAIDs, warfarin, clopidogrel, or controls. The positive-predictive-value of FOBT for advanced colonic neoplasia was computed for each group.

Results

During the study period, 1,126 patients underwent colonoscopy for a positive FOBT and met entry criteria. The average age of study participants was 69 years and most were men. The positive-predictive-value of FOBT for advanced colon neoplasia was significantly higher in the control group (30.5%) when compared to those on low-dose aspirin (20.5%; p = 0.003), NSAIDs (19.7%; p = 0.003), clopidogrel (7.3%; p = 0.002), or warfarin (20%; p = 0.05). The positive-predictive-value of FOBT was significantly lower for those on clopidogrel than those on low-dose aspirin (p = 0.04) and NSAIDs (p = 0.05), but not warfarin (p = 0.08). The positive-predictive-value for FOBT was similar for those on aspirin, NSAIDs, and warfarin. There was a linear trend between the number of number of positive FOBT cards and prevalence of advanced colon neoplasia (p = 0.01).

Conclusion

Anticoagulants and antiplatelet medications lower the positive-predictive-value of FOBT for advance colonic neoplasia and should be stopped if clinically feasible prior to stool collection.
Literatur
1.
Zurück zum Zitat Bond JH. The place of fecal occult blood test in colorectal cancer screening in 2006: the US perspective. Am J Gastroenterol. 2006;101:219–221.CrossRefPubMed Bond JH. The place of fecal occult blood test in colorectal cancer screening in 2006: the US perspective. Am J Gastroenterol. 2006;101:219–221.CrossRefPubMed
2.
Zurück zum Zitat CDC. Increasing use of colorectal cancer tests. Morb Mortal Wkly Rep. 2006;55:308–311. CDC. Increasing use of colorectal cancer tests. Morb Mortal Wkly Rep. 2006;55:308–311.
3.
Zurück zum Zitat El-Serag H, Petersen L, Hampel H, Richardson P, Cooper G. The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs. Arch Intern Med. 2006;166:2202–2208.CrossRefPubMed El-Serag H, Petersen L, Hampel H, Richardson P, Cooper G. The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs. Arch Intern Med. 2006;166:2202–2208.CrossRefPubMed
4.
Zurück zum Zitat Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124:544–560.CrossRefPubMed Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124:544–560.CrossRefPubMed
5.
Zurück zum Zitat Ransohoff D, Lang C. Screening for colorectal cancer with the fecal occult blood test: a background paper. Am Coll Physicians. 1997;126:811–822. Ransohoff D, Lang C. Screening for colorectal cancer with the fecal occult blood test: a background paper. Am Coll Physicians. 1997;126:811–822.
6.
Zurück zum Zitat Lieberman DA, Weiss DG. 380 FtVACSG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001;345:555–560.CrossRefPubMed Lieberman DA, Weiss DG. 380 FtVACSG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001;345:555–560.CrossRefPubMed
7.
Zurück zum Zitat Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365–1371.CrossRefPubMed Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365–1371.CrossRefPubMed
8.
Zurück zum Zitat Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471.CrossRefPubMed Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471.CrossRefPubMed
9.
Zurück zum Zitat Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;148:1472–1477.CrossRef Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;148:1472–1477.CrossRef
10.
Zurück zum Zitat Bond J. Fecal occult blood test screening for colorectal cancer. Gastrointest Endosc Clin N Am. 2002;12:11–21.CrossRefPubMed Bond J. Fecal occult blood test screening for colorectal cancer. Gastrointest Endosc Clin N Am. 2002;12:11–21.CrossRefPubMed
11.
Zurück zum Zitat Helm J, Russo M, Biddle A, Simpson K, Ransohoff D, Sandler R. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Am J Gastroenterol. 2000;95:3250–3258.CrossRefPubMed Helm J, Russo M, Biddle A, Simpson K, Ransohoff D, Sandler R. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Am J Gastroenterol. 2000;95:3250–3258.CrossRefPubMed
12.
Zurück zum Zitat Greenberg P, Cello J, Rockey D. Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease. Am J Med. 1996;100:598–604.CrossRefPubMed Greenberg P, Cello J, Rockey D. Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease. Am J Med. 1996;100:598–604.CrossRefPubMed
13.
Zurück zum Zitat Fleming J, Ahlquist D, McGill D, Zinsmeister A, Ellefson R, Schwartz S. Influence of aspirin and ethanol on fecal blood levels as determined by using the HemoQuant assay. Mayo Clin Proc. 1987;62:159–163.PubMed Fleming J, Ahlquist D, McGill D, Zinsmeister A, Ellefson R, Schwartz S. Influence of aspirin and ethanol on fecal blood levels as determined by using the HemoQuant assay. Mayo Clin Proc. 1987;62:159–163.PubMed
14.
Zurück zum Zitat Norfleet R. 1, 300 mg of aspirin daily does not cause positive fecal hemoccult tests. J Clin Gastroenterol. 1983;5:123–125.CrossRefPubMed Norfleet R. 1, 300 mg of aspirin daily does not cause positive fecal hemoccult tests. J Clin Gastroenterol. 1983;5:123–125.CrossRefPubMed
15.
Zurück zum Zitat Kahi C, Imperiale T. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am J Med. 2004;117:837–841.CrossRefPubMed Kahi C, Imperiale T. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am J Med. 2004;117:837–841.CrossRefPubMed
16.
Zurück zum Zitat Kewenter J, Svanvik J, Svensson C, Wallgren K. The diagnostic value of the hemoccult as a screening test in patients taking anticoagulants. Cancer. 1984;54:3054–3058.CrossRefPubMed Kewenter J, Svanvik J, Svensson C, Wallgren K. The diagnostic value of the hemoccult as a screening test in patients taking anticoagulants. Cancer. 1984;54:3054–3058.CrossRefPubMed
17.
Zurück zum Zitat Bini E, Rajapaksa R, Weinshel E. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol. 2005;100:1586–1592.CrossRefPubMed Bini E, Rajapaksa R, Weinshel E. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol. 2005;100:1586–1592.CrossRefPubMed
18.
Zurück zum Zitat Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med. 2005;352:287–289.CrossRefPubMed Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med. 2005;352:287–289.CrossRefPubMed
19.
Zurück zum Zitat van Hecken A, Depre M, Wynants K, et al. Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metabol Drug Interact. 1998;14:193–205.PubMed van Hecken A, Depre M, Wynants K, et al. Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metabol Drug Interact. 1998;14:193–205.PubMed
20.
Zurück zum Zitat Ecclissato C, Carvalho AF, Ferraz JG, de Nucci G, De Souza CA, Pedrazzoli J Jr. Prevalence of peptic lesions in asymptomatic, healthy volunteers. Dig Liver Dis. 2001;33(5):403–406.CrossRefPubMed Ecclissato C, Carvalho AF, Ferraz JG, de Nucci G, De Souza CA, Pedrazzoli J Jr. Prevalence of peptic lesions in asymptomatic, healthy volunteers. Dig Liver Dis. 2001;33(5):403–406.CrossRefPubMed
Metadaten
Titel
Fecal Occult Blood Test in Patients on Low-Dose Aspirin, Warfarin, Clopidogrel, or Non-steroidal Anti-inflammatory Drugs
verfasst von
Mandeep S. Sawhney
Heather McDougall
Douglas B. Nelson
John H. Bond
Publikationsdatum
01.06.2010
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 6/2010
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1150-4

Weitere Artikel der Ausgabe 6/2010

Digestive Diseases and Sciences 6/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.